These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37655659)

  • 1. Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors.
    Sun L; Kienzler JC; Reynoso JG; Lee A; Shiuan E; Li S; Kim J; Ding L; Monteleone AJ; Owens GC; Phillips JJ; Everson RG; Nathanson D; Cloughesy TF; Li G; Liau LM; Hugo W; Kim W; Prins RM
    J Clin Invest; 2023 Sep; 133(17):. PubMed ID: 37655659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The N
    Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
    Front Immunol; 2021; 12():653711. PubMed ID: 34354698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors.
    Musca B; Russo MG; Tushe A; Magri S; Battaggia G; Pinton L; Bonaudo C; Della Puppa A; Mandruzzato S
    Front Immunol; 2023; 14():1236824. PubMed ID: 37936683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma.
    Lee AH; Sun L; Mochizuki AY; Reynoso JG; Orpilla J; Chow F; Kienzler JC; Everson RG; Nathanson DA; Bensinger SJ; Liau LM; Cloughesy T; Hugo W; Prins RM
    Nat Commun; 2021 Nov; 12(1):6938. PubMed ID: 34836966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
    Genoud V; Espinoza FI; Marinari E; Rochemont V; Dietrich PY; McSheehy P; Bachmann F; Lane HA; Walker PR
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34403371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell sequencing reveals the immune landscape of breast cancer patients with brain metastasis.
    Zhou H; He X; Huang J; Zhong Y; Zhang L; Ao X; Zhao H; Hu S; Li H; Huang J; Huang H; Liang H
    Thorac Cancer; 2024 Mar; 15(9):702-714. PubMed ID: 38316626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade.
    Park JH; Kang I; Lee HK
    Front Immunol; 2022; 13():1044544. PubMed ID: 36591276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
    Song Y; Peng Y; Qin C; Wang Y; Yang W; Du Y; Xu T
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37777251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
    House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
    Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.
    Surendran A; Jenner AL; Karimi E; Fiset B; Quail DF; Walsh LA; Craig M
    J Pharmacol Exp Ther; 2023 Oct; 387(1):66-77. PubMed ID: 37442619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated microenvironment-associated genomic profiles identify LRRC15 mediating recurrent glioblastoma-associated macrophages infiltration.
    Tang H; Liu W; Xu Z; Zhao J; Wang W; Yu Z; Wei M
    J Cell Mol Med; 2021 Jun; 25(12):5534-5546. PubMed ID: 33960636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy.
    Gong X; Karchin R
    Sci Rep; 2023 Jan; 13(1):950. PubMed ID: 36653470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer.
    Gao Y; Stein MM; Kase M; Cummings AL; Bharanikumar R; Lau D; Garon EB; Patel SP
    Cancer Immunol Immunother; 2023 Feb; 72(2):339-350. PubMed ID: 35881197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell meta-analyses reveal responses of tumor-reactive CXCL13
    Liu B; Zhang Y; Wang D; Hu X; Zhang Z
    Nat Cancer; 2022 Sep; 3(9):1123-1136. PubMed ID: 36138134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma.
    Chiang NJ; Hou YC; Tan KT; Tsai HW; Lin YJ; Yeh YC; Chen LT; Hou YF; Chen MH; Shan YS
    Hepatol Int; 2022 Oct; 16(5):1137-1149. PubMed ID: 35780451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
    Trono P; Tocci A; Palermo B; Di Carlo A; D'Ambrosio L; D'Andrea D; Di Modugno F; De Nicola F; Goeman F; Corleone G; Warren S; Paolini F; Panetta M; Sperduti I; Baldari S; Visca P; Carpano S; Cappuzzo F; Russo V; Tripodo C; Zucali P; Gregorc V; Marchesi F; Nistico P
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37612043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMMUNE AND MOLECULAR CORRELATES OF RESPONSE TO IMMUNOTHERAPY REVEALED BY BRAIN-METASTATIC MELANOMA MODELS.
    Daugherty-Lopès A; Pérez-Guijarro E; Gopalan V; Rappaport J; Chen Q; Huang A; Lam KC; Chin S; Ebersole J; Wu E; Needle GA; Church I; Kyriakopoulos G; Xie S; Zhao Y; Gruen C; Sassano A; Araya RE; Thorkelsson A; Smith C; Lee MP; Hannenhalli S; Day CP; Merlino G; Goldszmid RS
    bioRxiv; 2024 Oct; ():. PubMed ID: 39372744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets.
    Varešlija D; Priedigkeit N; Fagan A; Purcell S; Cosgrove N; O'Halloran PJ; Ward E; Cocchiglia S; Hartmaier R; Castro CA; Zhu L; Tseng GC; Lucas PC; Puhalla SL; Brufsky AM; Hamilton RL; Mathew A; Leone JP; Basudan A; Hudson L; Dwyer R; Das S; O'Connor DP; Buckley PG; Farrell M; Hill ADK; Oesterreich S; Lee AV; Young LS
    J Natl Cancer Inst; 2019 Apr; 111(4):388-398. PubMed ID: 29961873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.